Hanmi Science (008930) Fundamentals 2026 — P/E 16.8x, Revenue Analysis | SniperIQ
Hanmi Science (008930) is a KR-listed Healthcare company in Medical - Distribution with a market capitalization of ₩2.25T, trading at ₩33250.00 on the KSC. This SniperIQ fundamentals page covers Hanmi Science's valuation (P/E 16.8x, P/B 2.3x), profitability (net margin 9.9%), revenue (₩1.36T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hanmi Science's market cap?
Hanmi Science (008930) has a market capitalization of approximately ₩2.25T, trading at ₩33250.00 on the KSC. Market cap moves with the live share price.
What is Hanmi Science's P/E ratio?
Hanmi Science's trailing twelve-month P/E ratio is 16.8x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hanmi Science?
Hanmi Science runs a net profit margin of 9.9%, a gross margin of 40.2%, and an operating margin of 8.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hanmi Science generate?
Hanmi Science reported revenue of ₩1.36T for fiscal year 2025, with net income of ₩118.4B and earnings per share (EPS) of 1748.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hanmi Science pay a dividend?
Hanmi Science offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hanmi Science financially healthy?
Hanmi Science carries a debt-to-equity ratio of 0.19x and a current ratio of 0.87x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hanmi Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hanmi Science (008930) the key facts are: market cap ₩2.25T, P/E 16.8x, revenue ₩1.36T, 52-week range 25600-55500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hanmi Science's full fundamentals live
Get Hanmi Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.